tiprankstipranks
Trending News
More News >
Sarepta Therapeutics (CH:AB3A)
:AB3A
Advertisement

Sarepta Therapeutics (AB3A) Price & Analysis

Compare
0 Followers

AB3A Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Biotechnology AdvancementsAnalysts view Sarepta Therapeutics as well-positioned to benefit from advancements in biotechnology and medical innovation.
Gene Therapy InnovationSarepta Therapeutics Inc. is gaining attention due to its focus on gene therapy, which is considered a promising field in medical innovation.
Product Uptake And Market ConfidenceSRPT's current valuation renders its risk/reward skewed to the upside given that Elevidys uptake is ramping up and sales could beat expectations.
Bears Say
Market UncertaintyThe cancellation of the R&D Day and uncertainty about the timing of data disclosure make it difficult to gain excitement or confidence ahead of the preliminary data.
Safety ConcernsSarepta Therapeutics announced a second non-ambulatory Elevidys patient died from acute liver failure, leading to the suspension of all Elevidys shipments for non-ambulatory DMD patients.
Safety Concerns And Product RisksThe potential death of an ambulatory Elevidys patient remains the biggest risk, which could trigger concerns about the market removal of Elevidys.

Sarepta Therapeutics News

AB3A FAQ

What was Sarepta Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 10 days.
    How were Sarepta Therapeutics’s earnings last quarter?
    Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported CHF1.505 earnings per share for the quarter, beating the consensus estimate of CHF0.663 by CHF0.843.
      Is Sarepta Therapeutics overvalued?
      According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Sarepta Therapeutics pay dividends?
        Sarepta Therapeutics does not currently pay dividends.
        What is Sarepta Therapeutics’s EPS estimate?
        Sarepta Therapeutics’s EPS estimate is -0.56.
          How many shares outstanding does Sarepta Therapeutics have?
          Currently, no data Available
          What happened to Sarepta Therapeutics’s price movement after its last earnings report?
          Sarepta Therapeutics reported an EPS of CHF1.505 in its last earnings report, beating expectations of CHF0.663. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Sarepta Therapeutics?
            Currently, no hedge funds are holding shares in CH:AB3A

            Company Description

            Sarepta Therapeutics

            Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

            Sarepta Therapeutics (AB3A) Earnings & Revenues

            AB3A Stock 12 Month Forecast

            Average Price Target

            CHF18.46
            eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
            Similar Stocks
            Company
            Price & Change
            Follow
            BioCryst
            Mesoblast
            Cogent Biosciences
            Arcutis Biotherapeutics
            Dyne Therapeutics

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis